high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

Summary

high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement (MONDO:0018813) is a cancer. A subtype of aggressive B-cell non-Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement
Mondo ID	MONDO:0018813
Orphanet	480541
UMLS	C4524190
MedGen	1617477
GARD	0021980
Is cancer (heuristic)	yes

Disease family

This is a subtype of aggressive B-cell non-Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › B-cell non-Hodgkin lymphoma › aggressive B-cell non-Hodgkin lymphoma › high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

Related subtypes (5): Burkitt lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, B-cell prolymphocytic leukemia, precursor B-cell acute lymphoblastic leukemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.